Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Mulder

Showing results (141-150 of 147) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 147 results.
AIDS (London, England)|February 24, 2001
The ADAM study continued: maintenance therapy after 50 weeks of induction therapyM H Reijers, G J Weverling, S Jurriaans, et al.
Nederlands Tijdschrift Voor Geneeskunde|September 6, 2001
[HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]M Jambroes, G J Weverling, P Reiss, et al.
AIDS (London, England)|August 26, 1998
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapyR M Hoetelmans, M H Reijers, G J Weverling, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 10, 2001
A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacyD M Burger, P W Hugen, R E Aarnoutse, et al.
The Journal of Infectious Diseases|June 1, 1996
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative GroupR T Schooley, C Ramirez-Ronda, J M Lange, et al.
International Journal of Antimicrobial Agents|March 13, 1999
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trialA M Been-Tiktak, C A Boucher, F Brun-Vezinet, et al.
Open Forum Infectious Diseases|December 4, 2015
Risk Factors for Sexual Transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men: A Case-Control StudyJoost W Vanhommerig, Femke A E Lambers, Janke Schinkel, et al.
Pageof 15

Showing results (141-150 of 147) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 147 results.
AIDS (London, England)|February 24, 2001
The ADAM study continued: maintenance therapy after 50 weeks of induction therapyM H Reijers, G J Weverling, S Jurriaans, et al.
Nederlands Tijdschrift Voor Geneeskunde|September 6, 2001
[HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]M Jambroes, G J Weverling, P Reiss, et al.
AIDS (London, England)|August 26, 1998
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapyR M Hoetelmans, M H Reijers, G J Weverling, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 10, 2001
A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacyD M Burger, P W Hugen, R E Aarnoutse, et al.
The Journal of Infectious Diseases|June 1, 1996
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative GroupR T Schooley, C Ramirez-Ronda, J M Lange, et al.
International Journal of Antimicrobial Agents|March 13, 1999
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trialA M Been-Tiktak, C A Boucher, F Brun-Vezinet, et al.
Open Forum Infectious Diseases|December 4, 2015
Risk Factors for Sexual Transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men: A Case-Control StudyJoost W Vanhommerig, Femke A E Lambers, Janke Schinkel, et al.
Pageof 15